The Placental Stem Cell Therapy for Neurological Disorders Market was valued at USD 464.96 Million and is projected to reach a market size of USD 1,806.95 Million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 21.4%.
Placental stem cells emerge from the placental blood and other bodily fluids of newborn infants. Plentiful perinatal stem cells are present within both placental blood and tissues. Cord blood stem cells and umbilical cord tissues constitute additional integral components of the placenta. Stem cell therapy stands acclaimed for ushering significant and innovative advancements in cancer management and healthcare. Notably, conditions such as cancer, vascular disorders, and neurological disorders find effective therapeutic solutions within these offerings. Stem cell therapy has recently emerged as a promising contender in the realm of gene therapy, offering potential for tissue repair and regeneration. Moreover, the industry is increasingly recognizing the medicinal potential of stem cells for disease and disorder management. The human placenta demonstrates positive impacts on the immune system, while therapeutic applications of placental components, including amniotic membranes, contribute to wound healing, burn treatment, and oral cavity restoration, fostering the expansion of this market. Although extensive research has largely mitigated the risks and challenges linked to the derivation and cultivation of Placental Stem Cells (PSCs), ethical considerations remain, with the development of induced pluripotent stem cells serving as a means to address these concerns. The increasing volume of experimental scientific investigations that focus on the therapeutic efficacy of placental stem cells for neurological disorder treatment, alongside the establishment of stem cell line banking, plays a pivotal role in propelling the growth of the placental stem cell therapy industry.
Key Market Insights:
In the pursuit of broadening the clinical uses of placental stem cell therapies, players in the field are actively embracing various technologies and methodologies. Their focus lies on maintaining a steady standard of stem cell quality, prompting a significant emphasis on advancements in biobanking technologies. This has led to extensive exploration and study of placental stem cell therapies' characteristics.
Allogeneic human amniotic epithelial cells (hAECs) are demonstrating promise in addressing conditions like leukemia and bronchopulmonary dysplasia (BPD) across multiple stages of clinical trials. The increasing prevalence of allogeneic stem cell transplantation procedures in industrialized countries has positively impacted the sales outlook within the placental stem cell therapy market.
Ongoing developments in cell-based treatments have increased the industry's interest in utilizing placental stem cell therapy for a range of illnesses. This expansion is propelling the potential for increased sales within the placental stem cell therapy market. Particularly in the context of neurological disorders, there is notable therapeutic effectiveness being observed in cell therapy products based on mesenchymal stem/stromal cells (MSCs).
Increasing advancement in the scientific, technological, and medical fields has been fueling the growth of Global Placental Stem Cell Therapy.
Recent swift advancements in the genetic engineering of human pluripotent stem cells (hPSCs) have facilitated enhancements in techniques for targeted differentiation, cell monitoring, gene function assessment, and genetic rectification. The emergence of nucleases-based technologies, including ZFNs, TALENs, and CRISPR/Cas9, holds the potential to streamline and make changes in genetic alterations in hPSCs and their subsequent generations, owing to their elevated success rates and simplified design procedures.
Increasing funding for stem cell research has been contributing to enhancing the growth of the market.
There is a higher need for improved treatments for diseases like auto-immune conditions, neurological problems, and heart diseases. This has led to more money being spent on studying cells and putting together all the research done so far. One of the main reasons the market is getting bigger is because a lot of money is being invested in researching and developing these treatments. Also, since more people need strong treatments to help them with their illnesses, the market is growing even more. Because researchers and both public and private organizations are putting in more effort and money, there are new chances for the market to grow faster.
The rise in the prevalence of neurological disorders and other chronic illnesses is augmenting the market for Placental stem cell therapy.
A large portion of the global population faces ongoing health issues. One out of every three adults across the world deals with chronic conditions. These persistent diseases have significantly affected the well-being and daily life of numerous individuals. Ailments like cancer, musculoskeletal and neurological disorders, long-lasting injuries, heart and digestive problems, and cancer itself can lead to hospitalization, lasting incapacity, reduced quality of life, and even death. Mesenchymal stem cells can enter and become part of various organs. They are used to treat diseases related to the lungs, spinal cord, autoimmune system, liver, bones, and cartilage. They also help address damage in multiple organs. The use of stem cells in managing conditions linked to inflammation, the immune system, and the breakdown of tissues proves to be an effective approach.
The expansion of the cell treatment market has faced obstacles due to its high costs. As people seek out the latest options for therapies, cell treatments have become a popular choice. Despite the growing demand, these treatments remain quite expensive to undergo. Simple joint injections, for instance, could cost around $1,000, while more complex procedures might reach up to $100,000. Additionally, the strict regulatory environment adds to the challenges faced by the market.
Even though there has been rapid progress in pluripotent stem cell (PSC) research over the past three decades, these cells are not yet fully understood for therapeutic use. The foundational principles of generating, characterizing, and cultivating PSCs are widely recognized. While much of the risk and issues tied to the creation and cultivation of PSCs have been largely addressed through research, ethical concerns persist. The development of induced pluripotent stem cells (iPSCs) is helping to tackle these ethical concerns.
The placental stem cell market is poised for significant growth, presenting a range of promising opportunities. Placental stem cells have shown remarkable versatility and efficacy in addressing neurological disorders. As research continues to uncover new therapeutic avenues, the market stands to benefit from the increasing demand for innovative and effective treatments. As public awareness and acceptance of regenerative medicine grow, the demand for alternative treatment options is on the rise. The placental stem cell market holds a wealth of opportunities driven by expanding clinical applications, technological advancements, collaborative efforts, and increasing patient demand. As research and innovation continue to pave the way, the market is poised to offer lucrative business opportunities in the coming years.
PLACENTAL STEM CELL THERAPY FOR NEUROLOGICAL DISORDERS MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
21.4% |
|
Segments Covered |
By Type, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Mesoblast Ltd., Pluristem Therapeutics, ReNeuron Group, AthersysInc., Cordlife India, LifeCell International Pvt. Ltd, Cryo-Cell International Inc., CBR Systems, Cellularity Inc., Cynata |
Allogeneic Placental Stem Cell Therapy
Autologous Placental Stem Cell Therapy
In 2022, allogeneic placental stem cell therapy has dominated the segment within the market due to its unique capability to establish a new immune system in patients when donor cells successfully integrate into the recipient's body. This approach holds significant potential for treating both cancerous and non-cancerous conditions, encompassing neurological disorders, acute and chronic leukemia, Hodgkin's lymphoma, adrenoleukodystrophy, bone marrow failure syndromes, and more, through allogeneic stem cell transplants.
The escalating population of individuals dealing with cancer has contributed to the growing demand for treatments like Omidubicel, an advanced cell therapy designed for individuals with blood cancer. This demand is expected to fuel expansion within this specific segment. The segment's growth is also attributed to its cost-effectiveness and the expanding accessibility of stem cell banking services.
Moreover, the proactive shift of several cell therapy companies towards developing allogeneic cell therapy products adds to the momentum of this segment's growth. As these developments continue, the landscape of allogeneic stem cell therapy is set to witness remarkable expansion, solidifying its position as a pivotal player in the realm of medical treatments.
Autologous Placental Stem Cell Therapy is the largest growing market during the forecast period.
Hospitals & Specialty Clinics
Clinics Research Organizations
Research Institutes & Academics
The clinical research organizations segment holds a dominant position in the market, with the highest market share in 2022. This dominance can be attributed to the upsurge in research and development and the accessibility of funding dedicated to cell-focused investigations, driven by the urgent requirement for more advanced and effective treatments targeting autoimmune, cardiovascular, and neurological disorders. Furthermore, the escalating desire for biologics and the expanding scope of research aimed at unearthing novel acquisition approaches that have potential applications in developing personalized medicines collectively contribute to the robust expansion of the clinical research organizations sector. Hospitals and Specialty Clinics are the largest growing market and are expected to hold a substantial market share during the forecast period.
North America
Europe
Asia-Pacific
South America
Middle East & Africa
In 2022, the North American region held the world’s 35% market share, making it the most dominant region in the segment. This can be attributed to the increasing allocation of research grants and both public and private investments dedicated to the advancement of safe and efficacious stem cell therapy products. Notably, the United States is a focal point, with a notable surge in clinical trials focused on placental stem cell applications, driving the overall growth trajectory in the region. Furthermore, the continuous evolution of placental stem cell therapy and the exceptional state of the healthcare sector synergistically contribute to the remarkable expansion of the market across North America.
Asia-Pacific region is the largest growing region and emerges as the foremost driver of growth on a global scale. Projections suggest that the Asia-Pacific stem cell therapy sector will experience substantial expansion over the upcoming decade. This projection is supported by the active participation of numerous public and private foundations, dedicated to providing financial backing and support for initiatives in stem cell-based research. The extensive landscape of the stem cell therapy industry encompasses a diverse array of drugs derived from stem cells, targeting an assortment of ailments such as cancer, tissue regeneration, injuries, and accidents.
COVID-19 Impact on the Global Placental Stem Cell Therapy for Neurological Disorders Market:
The outbreak prompted a series of challenges that affected both the demand and supply aspects of this specialized therapeutic area. Moreover, clinical trials, which are essential for advancing and validating new therapies, faced disruptions due to lockdowns, travel restrictions, and reduced access to medical facilities. However, amidst these challenges, the pandemic also shed light on the potential benefits of stem cell therapies, including those derived from placental sources. Research into the immunomodulatory and anti-inflammatory properties of placental stem cells gained attention in the context of treating COVID-19 complications. The overall impact of COVID-19 on the Placenta stem cell market was moderate and it is set to experience a huge comeback with an array of opportunities.
Latest trends/ Developments:
Industry participants are showing a strong inclination towards integrating advanced technologies and methodologies to maintain a consistent level of stem cell quality. This strategic approach aims to broaden the scope of clinical applications for placental stem cell therapies.
Within the placental stem cell therapy sector, enterprises are directing their attention toward achieving a dependable and high-quality cell production process. Notably, ReNeuron, a notable player engaged in developing therapeutics derived from stem cells specific to the retina, is intensifying its endeavors to harmonize scientific precision with a touch of artistry. This strategic approach aims to ensure unwavering uniformity in cell manufacturing, a critical aspect for effectively addressing conditions like retinitis pigmentosa.
The placental stem cell therapy market is witnessing a growing interest in utilizing allogeneic stem cell transplantation as a comprehensive approach to treating neurological disorders. The field of cell therapy for neurological conditions is rapidly progressing. Notably, during the evaluation of various cell types, each demonstrates its distinct benefits and limitations due to their specific molecular mechanisms. As a result, the idea of conducting combined transplantation of two or more types of cells has emerged as a promising concept.
There is a notable shift towards realizing potential therapeutic effects through the transplantation of a varied array of autologous or allogeneic stem/progenitor cells. This includes cell types such as embryonic and induced pluripotent stem cells, which have showcased encouraging outcomes in preclinical studies involving animal models of neurological ailments. As a consequence, these constructive research findings are currently evolving into viable revenue opportunities for companies engaged in this specific sector.
Key Players:
Mesoblast Ltd.
Pluristem Therapeutics
ReNeuron Group
AthersysInc.
Cordlife India
LifeCell International Pvt. Ltd
Cryo-Cell International Inc.
CBR Systems
Cellularity Inc.
Cynata
In December 2022, Celularity Inc., a clinical-stage biotech firm dedicated to the advancement of allogeneic cell therapies and biomaterial products sourced from the placenta, revealed its attainment of Halal Certification for its business models. This certification extends to its biomaterial products in the commercial stage, as well as its cellular therapeutic programs at both clinical and investigational stages.
In May 2022, ViaCyte, Inc. collaborated with SQZ Biotechnologies to jointly develop and bring to market microfluidic intracellular delivery technology for research-use-only (RUO) purposes. This partnership facilitates the exchange of innovative research in hematopoietic stem cell engineering between both entities involved in the market.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The Placental Stem Cell Therapy for Neurological Disorders Market was valued at USD 464.96 Million and is projected to reach a market size of USD 1,806.95 Million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 21.4%.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
